Genentech and Biogen Idec received approval from the FDA for the therapeutic antibody Rituxan in combination with methotrexate (MTX) to reduce signs and symptoms in adult patients with moderate-to-severe rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect m...